CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Clinical trial NCT03638141 · COMPLETED

Trial details

NCT number: NCT03638141
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Intermediate Stage of Hepatocellular Carcinoma Hepatocellular Carcinoma

Start date: 2019-10-02
Primary completion: 2024-08-20
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.